ARTICLE | Company News
AstraZeneca, Boehringer Ingelheim, Eli Lilly, J&J, Mitsubishi Tanabe Pharma sales and marketing update
May 30, 2016 7:00 AM UTC
The agency said the drugs had incremental cost-effectiveness ratios (ICERs) per quality adjusted life year (QALY) of L20,000-L30,000 ($29,006-$43,509) and were therefore cost-effective compared with ...